GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins

Nature Biotechnology

Volumn 32, Issue 5, 2014, Pages 485-489

  Meuris, Leander ^a,b   Santens, Francis ^a,b   Elson, Greg ^c   Festjens, Nele ^a,b   Boone, Morgane ^a,b   Dos Santos, Anaëlle ^c   Devos, Simon ^b   Rousseau, François ^c   Plets, Evelyn ^a,b   Houthuys, Erica ^a,b   Malinge, Pauline ^c   Magistrelli, Giovanni ^c   Cons, Laura ^c   Chatel, Laurence ^c   Devreese, Bart ^b   Callewaert, Nico ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c NOVIMMUNE SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ENGINEERING; ESTERIFICATION; GLYCOSYLATION; MAMMALS; POLYSACCHARIDES;

CONSISTENT PERFORMANCE; MAMMALIAN PROTEINS; MULTISTEP PROCESS; PROTEIN PURIFICATION; REDUCED COMPLEXITY; REPRODUCIBILITIES; THERAPEUTIC EFFICACY; THERAPEUTIC PROTEIN;

PROTEINS;

CHITOBIOSE; GLYCOSYLTRANSFERASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEXOSE; IMMUNOGLOBULIN G; N ACETYLNEURAMINIC ACID; RECOMBINANT PROTEIN; SIALIDASE; POLYSACCHARIDE;

ANIMAL CELL; ARTICLE; CAPILLARY ELECTROPHORESIS; CELL PROLIFERATION; GEL FILTRATION CHROMATOGRAPHY; GLYCODELETE; HEAVY CHAIN; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MAMMAL CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; SURFACE PLASMON RESONANCE; ANIMAL; CHEMISTRY; GENETICS; GLYCOSYLATION; HUMAN; METABOLISM; MOUSE; PROCEDURES;

ANIMALS; GLYCOSYLATION; HUMANS; MICE; POLYSACCHARIDES; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 84900323466     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2885     Document Type: Article

References (30)

1. Ferrara, C. et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: infuence of Golgi enzyme localization domain and co-expression of heterologous ß1, 4-N-acetylglucosaminyltransferase III and Golgi a-mannosidase II. Biotechnol. Bioeng. 93, 851-861 (2006).
2. Elliott, S. et al. Control of rHuEPO biological activity: the role of carbohydrate. Exp. Hematol. 32, 1146-1155 (2004).
3. Jacobs, P.P., Geysens, S., Vervecken, W., Contreras, R. & Callewaert, N. Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology. Nat. Protoc. 4, 58-70 (2008).
4. Hamilton, S.R. et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313, 1441-1443 (2006).
5. Herter, S. et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol. Cancer Ther. 12, 2031-2042 (2013).
6. Kanda, Y. et al. Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol. Bioeng. 94, 680-688 (2006).
7. Reeves, P.J., Callewaert, N., Contreras, R. & Khorana, H.G. Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N- acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc. Natl. Acad. Sci. USA 99, 13419-13424 (2002).
8. Stals, I. et al. Identifcation of a gene coding for a deglycosylating enzyme in Hypocrea jecorina. FEMS Microbiol. Lett. 303, 9-17 (2010).
9. Grundmann, U., Nerlich, C, Rein, T. & Zettlmeissl, G. Complete cDNA sequence encoding human ß-galactoside a-2, 6-sialyltransferase. Nucleic Acids Res. 18, 667 (1990).
10. Verstraete, K. et al. Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex. Blood 118, 60-68 (2011).
11. Bernales, S., Papa, F.R. & Walter, P. Intracellular signaling by the unfolded protein response. Annu. Rev. Cell Dev. Biol. 22, 487-508 (2006).
12. Lee, F. et al. Isolation of cDNA for a human granulocyte-macrophage colony-stimulating factor by functional expression in mammalian cells. Proc. Natl. Acad. Sci. USA 82, 4360-4364 (1985).
13. Forno, G. et al. N-and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line. Eur. J. Biochem. 271, 907-919 (2004).
14. Crispin, M. et al. Inhibition of hybrid-and complex-type glycosylation reveals the presence of the GlcNAc transferase I-independent fucosylation pathway. Glycobiology 16, 748-756 (2006).
15. Ericsson, U.B., Hallberg, B.M., DeTitta, G.T., Dekker, N. & Nordlund, P. Thermofuor-based high-throughput stability optimization of proteins for structural studies. Anal. Biochem. 357, 289-298 (2006).
16. Kitamura, T. et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol. 140, 323-334 (1989).
17. Mössner, E. et al. Increasing the effcacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115, 4393-4402 (2010).
18. Nallet, S. et al. Glycan variability on a recombinant IgG antibody transiently produced in HEK-293E cells. N. Biotechnol. 29, 471-476 (2012).
19. Jefferis, R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8, 226-234 (2009).
20. Roopenian, D.C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715-725 (2007).
21. Lux, A., Yu, X., Scanlan, C.N. & Nimmerjahn, F. Impact of immune complex size and glycosylation on IgG binding to human FcyRs. J. Immunol. 190, 4315-4323 (2013).
22. Hamblin, M.W. & Metcalf, M.A. Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol. Pharmacol. 40, 143-148 (1991).
23. Tradtrantip, L., Ratelade, J., Zhang, H. & Verkman, A.S. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann. Neurol. 73, 77-85 (2013).
24. Nandakumar, K.S. et al. Dominant suppression of infammation by glycan-hydrolyzed IgG. Proc. Natl. Acad. Sci. USA 110, 10252-10257 (2013).
25. Allhorn, M. & Collin, M. Sugar-free antibodies-The bacterial solution to autoimmunity? Ann. NY Acad. Sci. 1173, 664-669 (2009).
26. Anonymous. Biosimilar, biobetter and next generation therapeutic antibodies. MAbs 3, 107-110 (2011).
27. MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966-968 (2010).
28. Tada, H., Shiho, O., Kuroshima, K., Koyama, M. & Tsukamoto, K. An improved colorimetric assay for interleukin 2. J. Immunol. Methods 93, 157-165 (1986).
29. Ramsland, P.A. et al. Structural basis for Fc γRIIa recognition of human IgG and formation of infammatory signaling complexes. J. Immunol. 187, 3208-3217 (2011).
30. Magistrelli, G. et al. Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies. J. Immunol. Methods 375, 20-29 (2012).